USPTO Examiner ARIETI RUTH SOPHIA - Art Unit 1635

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19268623COMPOUNDS AND METHODS FOR REDUCING PLN EXPRESSIONJuly 2025January 2026Allow610YesNo
19219917COMPOSITIONS AND METHODS FOR TREATMENT OF KIDNEY DISEASEMay 2025March 2026Allow1020YesNo
18977470COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024November 2025Allow1110NoNo
18977518COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024November 2025Allow1110NoNo
18977579COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024October 2025Allow1110NoNo
18976043COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024January 2026Allow1310YesNo
18976118COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024October 2025Allow1110NoNo
18976156COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024October 2025Allow1110NoNo
18932078COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024April 2025Allow520YesNo
18928880CELL DEATH-INDUCING DFFA-LIKE EFFECTOR B (CIDEB) IRNA COMPOSITIONS AND METHODS OF USE THEREOFOctober 2024May 2025Allow610YesNo
18898720NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF TRANSFERRIN RECEPTOR 2September 2024September 2025Allow1121YesNo
18819737RNAi Agents for Inhibiting Expression of Inhibin Subunit Beta E (INHBE), Pharmaceutical Compositions Thereof, and Methods of UseAugust 2024March 2025Allow610YesNo
18791380ADVANCED RNA TARGETING (ARNATAR)July 2024January 2026Abandon1821YesNo
18765286RESTORATION OF THE CFTR FUNCTION BY SPLICING MODULATIONJuly 2024April 2025Allow920YesNo
18741110ANTISENSE OLIGONUCLEOTIDE TARGETING ATN1 MRNA OR PRE-MRNAJune 2024December 2024Allow710YesNo
18739091COMPOSITION FOR REGULATING PRODUCTION OF PROTEINSJune 2024January 2025Allow710YesNo
18646631APTAMERS FOR BINDING TO A MEMBRANE-BASED LIPIDApril 2024December 2024Allow811NoNo
18582317COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDFebruary 2024March 2025Allow1331YesNo
18435472APTAMER FOR SPECIFICALLY RECOGNIZING SOLUBLE ST2 PROTEIN AND APPLICATION OF THE SAMEFebruary 2024September 2024Allow710YesNo
18516722COMPOSITIONS AND METHODS FOR THE TARGETING OF PCSK9November 2023January 2026Allow2640YesNo
18470687CFTR-MODULATING COMPOSITIONS AND METHODSSeptember 2023November 2024Allow1421YesNo
17781876SIRNA CONJUGATE, DOUBLE-STRANDED SIRNA CONJUGATE, SALT THEREOF AND APPLICATION THEREOFJune 2022November 2025Abandon4101NoNo
17720996FN3 Domain-siRNA Conjugates and Uses ThereofApril 2022November 2024Allow3121YesNo
17671688METHOD OF TREATING AGE-RELATED MACULAR DEGENERATIONFebruary 2022November 2023Abandon2131NoNo
17590754ENHANCED OLIGONUCLEOTIDES FOR INHIBITING RTEL1 EXPRESSIONFebruary 2022September 2023Allow1910YesNo
17547879ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9December 2021March 2025Allow3931YesNo
17542055POLYMER NANOPARTICLE AND DNA NANOSTRUCTURE COMPOSITIONS AND METHODS FOR NON-VIRAL DELIVERYDecember 2021June 2024Abandon3120NoNo
17542046T-LYMPHOCYTE BINDING APTAMERSDecember 2021July 2024Allow3121NoNo
17540569Antisense Oligonucleotides Targeting ATXN3December 2021January 2024Abandon2511NoNo
17535070SINGLE-NUCLEI CHARACTERIZATION OF AMYOTROPHIC LATERAL SCLEROSIS FRONTAL CORTEXNovember 2021October 2023Abandon2301NoNo
17456239DUAL FUNCTIONAL EXPRESSION VECTORS AND METHODS OF USE THEREOFNovember 2021September 2023Abandon2211NoNo
17455528CONJUGATES OF S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS HAVING ENHANCED LIVER TARGETINGNovember 2021November 2024Abandon3631YesNo
17528851mRNA NANOCAPSULE AND USE IN PREPARATION OF ANTIVIRAL DRUGSNovember 2021March 2024Abandon2811YesNo
17524586NOVEL RNA TRANSCRIPTNovember 2021June 2024Abandon3121NoNo
17522418COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDSNovember 2021September 2023Abandon2210NoNo
17451428COMPOSITIONS AND METHODS FOR MODULATING MYC TARGET PROTEIN 1October 2021December 2024Allow3830YesNo
17598150Inhibition of Monoamine Oxidase Subtype A (MAOA) Mitigates Cardiovascular CalcificationSeptember 2021May 2025Abandon4401NoNo
17398252METHODS FOR DETERMINING INCREASED RISK OF CANCER DEVELOPMENT AND TREATING THE SAMEAugust 2021November 2024Abandon3921NoNo
17365777SYSTEMS, METHODS, AND COMPOSITIONS FOR RNA-GUIDED RNA-TARGETING CRISPR EFFECTORSJuly 2021January 2024Allow3111YesNo
17417718TREATMENT OF SPINAL CONDITIONS WITH CHIMERA DECOYJune 2021April 2025Abandon4610NoNo
17415420METHODS OF TREATMENT AND DIAGNOSIS OF TUMOURSJune 2021November 2025Abandon5321NoNo
17415262MIRNA FOR USE IN THERAPYJune 2021March 2025Abandon4501NoNo
17298415COMPOUNDS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASEMay 2021February 2026Allow5721YesNo
17303051dsRNA Directed to Coronavirus ProteinsMay 2021April 2024Abandon3521NoNo
17319291MESSENGER RNA ENCODING CAS9 FOR USE IN GENOME-EDITING SYSTEMSMay 2021August 2024Allow3931NoNo
17285569Methods for Treating Oculopharyngeal Muscular Dystrophy (OPMD)April 2021February 2024Abandon3411NoNo
17231588CONTROL OF REPLICATION AND TRANSCRIPTION OF SELF-REPLICATING RNA IN RESPONSE TO SMALL MOLECULESApril 2021July 2024Allow3930YesNo
17282502METHOD FOR TREATING RETINAL DEGENERATION DISEASE BY ADMINISTERING NUCLEOLIN POLYNUCLEOTIDE OR POLYPEPTIDEApril 2021January 2025Abandon4511NoNo
17213787RNAi Agents For Inhibiting Expression Of PNPLA3, Pharmaceutical Compositions Thereof, And Methods Of UseMarch 2021May 2024Allow3840YesNo
17204480OLIGONUCLEOTIDES FOR MAPT MODULATIONMarch 2021February 2026Abandon5931NoYes
17275959RNAi Agents for Inhibiting Expression of 17beta-HSD Type 13 (HSD17B13), Compositions Thereof, and Methods of UseMarch 2021September 2025Allow5521YesNo
16969314APTAMER FOR SCLEROSTIN AND USE THEREOFMarch 2021February 2025Allow5431YesNo
17187018COMPOUNDS AND METHODS FOR MODULATING SMN2February 2021May 2025Abandon5140YesNo
17271401POLYNUCLEOTIDES ENCODING VERY LONG-CHAIN ACYL-COA DEHYDROGENASE FOR THE TREATMENT OF VERY LONG-CHAIN ACYL-COA DEHYDROGENASE DEFICIENCYFebruary 2021December 2024Abandon4610NoNo
17268654NUCLEIC ACIDS AND NUCLEIC ACID ANALOGS FOR TREATING, PREVENTING, AND DISRUPTING PATHOLOGICAL POLYNUCLEOTIDE-BINDING PROTEIN INCLUSIONSFebruary 2021September 2025Allow5521YesNo
17266275SYSTEMS AND METHODS FOR APTAMER-BASED INTRACELLULAR DELIVERY OF A PAYLOAD USING NANONEEDLESFebruary 2021April 2025Abandon5011NoNo
17266069MICRORNA-BASED THERAPY TARGETED AGAINST LCP-1 POSITIVE CANCERSFebruary 2021June 2024Allow4131YesNo
17163761NUCLEIC ACID APTAMERSFebruary 2021March 2024Abandon3721NoNo
17262052EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHYJanuary 2021November 2023Abandon3411NoNo
17261653SMALL CELL LUNG CANCER THERAPEUTIC AGENT CONTAINING OLIGONUCLEOTIDEJanuary 2021September 2023Allow3121YesNo
17253760COMPOSITION COMPRISING ANTISENSE OLIGONUCLEOTIDE AND USE THEREOF FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHYDecember 2020January 2024Abandon3720YesNo
17058989CYTOTOXIC FLUOROPYRIMIDINE POLYMERS AND METHODS OF USE THEREOFNovember 2020January 2025Allow5020YesNo
17104562SINGLE BASE EDITING TOOLS WITH PRECISE ACCURACYNovember 2020January 2025Abandon5021NoNo
16951092IMMUNOMODULATORY THERAPEUTIC MRNA COMPOSITIONS ENCODING ACTIVATING ONCOGENE MUTATION PEPTIDESNovember 2020July 2025Abandon5611NoNo
16951161COMPOSITIONS AND METHODS FOR INHIBITING THE PRODUCTION OR ACTIVITY OF D-2HYDROXYGLUTARATE IN SUBJECTS AFFLICTED WITH CANCERNovember 2020September 2024Abandon4621NoNo
17098571SYSTEMS, METHODS, AND COMPOUNDS FOR PROVIDING CHAPERONE ACTIVITY TO PROTEINSNovember 2020May 2023Allow3011NoNo
17055378COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASENovember 2020January 2025Allow5020YesNo
17093225METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATIC AND METABOLIC DISEASESNovember 2020May 2025Abandon5521NoNo
17049061COMPOSITIONS AND METHODS FOR HEMOGLOBIN PRODUCTIONOctober 2020March 2026Allow6031YesNo
17038704TREATMENT OF CANCER BY SYSTEMIC ADMINISTRATION OF DBAIT MOLECULESSeptember 2020November 2023Abandon3710NoNo
17036257SYNTHETIC NON-CODING RNASSeptember 2020March 2026Allow6031YesNo
17040796GUIDE RNA FOR HSV-1 GENE EDITING AND METHOD THEREOFSeptember 2020March 2025Abandon5411NoNo
17040629CRISPR/Cas9-Mediated Exon-Skipping Approach for USH2A-Associated Usher SyndromeSeptember 2020February 2025Allow5321YesNo
16982733MODULATION OF HSD17B13 EXPRESSIONSeptember 2020January 2025Abandon5221NoNo
17022678BRANCHED LIPID CONJUGATES OF siRNA FOR SPECIFIC TISSUE DELIVERYSeptember 2020March 2025Allow5431YesYes
16981052IN SITU METHODS OF INDUCING OF IMMUNE RESPONSESeptember 2020December 2025Abandon6031NoNo
16979892A DBAIT MOLECULE AGAINST ACQUIRED RESISTANCE IN THE TREATMENT OF CANCERSeptember 2020December 2024Abandon5120NoNo
16970193ANTISENSE OLIGONUCLEOTIDES FOR RNA EDITINGAugust 2020July 2023Abandon3501NoNo
16970090C/EBP ALPHA SARNA COMPOSITIONS AND METHODS OF USEAugust 2020May 2024Abandon4620NoYes
16970004MODIFIED VIRAL CAPSIDSAugust 2020October 2024Abandon5011NoNo
16754714METHODS AND COMPOSITIONS FOR EXPANSION OF CELL POPULATIONAugust 2020March 2025Allow5912YesNo
16968861TUMOR ENVIRONMENT-SPECIFIC EXPRESSION OF CHIMERIC ANTIGEN RECEPTORSAugust 2020August 2025Abandon6031YesNo
16985779COMPOUNDS OF CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE THEREOFAugust 2020January 2025Abandon5321NoNo
15733306GAPMER OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGEJune 2020May 2024Abandon4720NoNo
16954625HIGH MOBILITY GROUP BOX-1 (HMGB1) IRNA COMPOSITIONS AND METHODS OF USE THEREOFJune 2020August 2024Abandon5031NoNo
16763180MANIPULATION OF THE RETINOIC ACID SIGNALING PATHWAYMay 2020October 2024Abandon5321NoNo
16649105EXPRESSION SYSTEMS THAT FACILITATE NUCLEIC ACID DELIVERY AND METHODS OF USEMarch 2020December 2025Abandon6041NoNo
16647728EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHYMarch 2020September 2023Abandon4211NoNo
16796439Optimized RPE65 Promoter and Coding SequencesFebruary 2020December 2023Allow4610YesNo
16595924MODULATION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT3) EXPRESSIONOctober 2019January 2023Abandon4001NoNo
15501238APTAMERS FOR USE AGAINST AUTOANTIBODY-ASSOCIATED DISEASESFebruary 2017December 2025Allow60131YesYes

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ARIETI, RUTH SOPHIA.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
1
Examiner Affirmed
1
(100.0%)
Examiner Reversed
0
(0.0%)
Reversal Percentile
0.5%
Lower than average

What This Means

With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
6
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
6
(100.0%)
Filing Benefit Percentile
0.5%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner ARIETI, RUTH SOPHIA - Prosecution Strategy Guide

Executive Summary

Examiner ARIETI, RUTH SOPHIA works in Art Unit 1635 and has examined 66 patent applications in our dataset. With an allowance rate of 34.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.

Allowance Patterns

Examiner ARIETI, RUTH SOPHIA's allowance rate of 34.8% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by ARIETI, RUTH SOPHIA receive 2.03 office actions before reaching final disposition. This places the examiner in the 53% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ARIETI, RUTH SOPHIA is 46 months. This places the examiner in the 10% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +72.7% benefit to allowance rate for applications examined by ARIETI, RUTH SOPHIA. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 22.7% of applications are subsequently allowed. This success rate is in the 30% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 57.1% of cases where such amendments are filed. This entry rate is in the 83% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 66.7% of appeals filed. This is in the 47% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 85.7% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.